On November 12, 2026, a major piece of the federal hemp definition changes. Intermediate and final hemp-derived cannabinoid products containing cannabinoids that are not capable of being naturally produced by a Cannabis sativa L. plant will no longer qualify as hemp. To the extent those products fall within the Controlled Substances Act's definitions of marijuana or THC, they will be treated as controlled substances.
That change is scheduled to arrive three days after this article's publication, on Thursday, November 12. It also arrives nine months after the U.S. Food and Drug Administration was supposed to publish the scientific lists that would identify which cannabinoids can and cannot be naturally produced by the plant.
The lists do not exist.
Congress Ordered Four Documents. The FDA Published None.
The missing guidance originates in Section 781 of Public Law 119-37, enacted November 12, 2025.
The legislation rewrote the federal definition of hemp under 7 U.S.C. § 1639o and instructed the FDA, in consultation with other relevant federal agencies, to publish four items within 90 days of the law's enactment.
The deadline was February 10, 2026.
Congress requested:
- A complete list of naturally occurring cannabinoids: all cannabinoids known to the FDA to be capable of being naturally produced by a Cannabis sativa L. plant, as reflected in peer-reviewed literature. - A list of naturally occurring THC-class cannabinoids: every THC-class cannabinoid known to the agency to occur naturally in the cannabis plant. - A list of other THC-like cannabinoids: compounds that have similar effects to THC-class cannabinoids or are marketed as having similar effects. - Clarification of the word container: additional information and specificity explaining what constitutes a container under the new law.
These were not optional recommendations. Congress directed the FDA to publish the documents within 90 days of enactment, and the agency was expected to consult other relevant federal agencies in preparing them.
But the deadline passed without them.
In its October 28, 2026 Legal Sidebar, the Congressional Research Service (CRS) stated: "As of the date of the publication of this Legal Sidebar, FDA has not published any of these items."
The CRS had already flagged the missing documents in May and September 2026. Its October report marked at least the third time the service had identified the gap.
As of November 9, none of the four items has appeared on FDA.gov or in the Federal Register.
The November 12 Deadline Arrives Before the Answer
The new federal hemp definition does not take effect all at once.
Public Law 119-103, Section 2019, delayed most of the changes until December 11, 2026. However, one provision takes effect November 12.
Beginning Thursday, intermediate and final hemp-derived cannabinoid products containing cannabinoids not capable of being naturally produced by a Cannabis sativa L. plant will stop being classified as hemp.
To the extent those products fall within the Controlled Substances Act's definitions of marijuana or THC, they will be treated as controlled substances.
That distinction is important.
The November 12 change is not the entire new hemp definition. It is specifically the naturally-producible exclusion.
The remaining provisions are scheduled for December 11.
This creates an immediate classification problem. The law establishes the test, but the federal agency assigned to provide the scientific answer has not published the lists that would make that test straightforward to apply.
The statute does not make the November 12 exclusion conditional on the FDA publishing those documents. The exclusion takes effect regardless of whether the guidance exists.
Which Cannabinoids Can the Plant Actually Produce?
The central question is scientific: can a particular cannabinoid be naturally produced by the cannabis plant?
Some compounds present a clearer case than others.
THC-O, for example, does not occur naturally in cannabis.
The Congressional Research Service describes its production as involving the conversion of cannabis-derived CBD to delta-8 THC and then adding acetic anhydride.
The Drug Enforcement Administration separately addressed THC-O in a February 13, 2023 letter, determining that it is a Schedule I controlled substance.
But other compounds present a more complicated classification question.
Which compounds fall on which side of that line is contested: industry analysts classify borderline compounds such as THCP, delta-10 and CBL differently, and no official list settles the question.
On May 4, 2026, the DEA established a separate Schedule I listing and drug code for HHC. The agency clarified that HHC was already controlled as a Schedule I tetrahydrocannabinol; the new rule did not change its existing status.
These individual determinations illustrate what is happening while the FDA's broader guidance remains unpublished: agencies are addressing products one by one rather than through the comprehensive lists Congress ordered.
The November 12 rule does not simply ask whether a compound was made in a laboratory. It asks whether the compound is capable of being naturally produced by the plant.
That distinction matters because the statutory test concerns the compound's natural production capability, not merely its manufacturing method.
The Federal Agencies Already Disagree on How to Read Hemp Law
The missing lists also leave an existing legal conflict unresolved.
The DEA's 2020 interim final rule states that all synthetically derived tetrahydrocannabinols remain Schedule I controlled substances.
But the Fourth Circuit Court of Appeals reached a different conclusion under the 2018 Farm Bill in Anderson v. Diamondback Investment Group on September 4, 2024.
The Fourth Circuit rejected the argument that THC-O was automatically illegal under the 2018 Farm Bill simply because it was produced through chemical processing. The court reasoned that cannabinoids derived from cannabis could qualify as hemp if they met the statutory delta-9 THC threshold, regardless of their manufacturing method.
However, the court ultimately affirmed the judgment against the plaintiff because she had not provided evidence establishing that the products she used contained no more than 0.3% delta-9 THC. The decision therefore addressed the legal treatment of cannabis-derived cannabinoids without establishing that her specific products were compliant — and as a Fourth Circuit decision, it does not bind every federal court.
The two positions illustrate the complications surrounding naturally occurring and synthetically derived compounds.
The new federal definition changes the statutory framework, but Congress assigned the FDA a specific role: publish lists that would distinguish naturally producible cannabinoids from those that are not.
Without those lists, businesses face a classification environment shaped by statutory language, existing agency positions and court decisions, rather than a single authoritative federal reference.
HHS Said the Lists Would Be Published on Time
Before the February deadline, a spokesperson for the Department of Health and Human Services told Marijuana Moment that the lists were intended to be published on time in the Federal Register.
They never appeared.
Marijuana Moment subsequently sent the FDA several requests for an update. According to its reporting, the agency has not replied.
That leaves a straightforward distinction between what Congress ordered and what the agency has delivered.
Congress requested four documents within 90 days.
The FDA missed the February 10 deadline, and the November 12 effective date is now approaching without the promised scientific guidance.
Manufacturers Are Being Asked to Comply Without the Full Definitions
The uncertainty has practical consequences for businesses producing and selling hemp-derived cannabinoid products.
Jim Higdon, cofounder and chief communications officer of Cornbread Hemp, told Marijuana Moment: "It is difficult to comply with the law while key definitions are still in question… Without knowing the definition of container or exact list of cannabinoids that are covered by the ban, how does one comply?"
The U.S. Hemp Roundtable estimates that the new federal definition could eliminate approximately 95% of the current hemp-derived product marketplace. That figure is an industry projection, not an official government estimate.
Compliance analysts have also noted that the naturally-produced-versus-synthetic determination increasingly rests on manufacturers' own records.
The immediate challenge is determining which cannabinoids meet the new statutory definition before the November 12 cutoff.
The uncertainty does not mean every cannabinoid is impossible to classify. THC-O, for example, has a clear record as a compound that does not occur naturally. But the contested middle of the market — compounds classified differently by different analysts — remains without a single published federal answer.
December 11 Brings the Rest of the Federal Changes
The November 12 exclusion is only the first stage.
On December 11, the remaining provisions of the new federal definition are scheduled to take effect.
These include:
- A 0.3% total-THC standard for hemp plants, counting THCA as well as delta-9 THC. - The exclusion of viable seeds from plants exceeding the applicable THC threshold. - The exclusion of cannabinoids synthesized or manufactured outside the plant. - Restrictions on intermediate hemp-derived cannabinoid products, including products exceeding the applicable cannabinoid thresholds or intermediate products marketed or sold directly to end consumers as finished products. - A maximum of 0.4 milligrams per container for final hemp-derived products, counting combined total tetrahydrocannabinols (including THCA) plus other cannabinoids with similar effects, or marketed to have similar effects, as determined by the Secretary of Health and Human Services.
The container provision is particularly relevant to manufacturers packaging finished products.
The statute defines a container as the innermost wrapping or packaging in direct contact with the product.
Examples include jars, bottles, bags, boxes, packets, cans, cartons and cartridges.
Bulk shipping packaging is not the container under this definition.
The 0.4-milligram limit applies per container. The statute does not establish a separate single-serving rule.
The FDA was specifically ordered to provide additional information and specificity about the term container. That clarification has also not been published.
Congress Has Not Reversed Course, and the FDA Has Not Explained the Delay
Several bills seeking to change the timeline or repeal the new federal definition remain pending.
H.R. 7024, H.R. 7010 and S. 3686 would delay implementation of the new definition by another two years.
H.R. 6209 would repeal it.
None has been enacted.
The Congressional Research Service has identified uncertainty surrounding how aggressively federal agencies will enforce the new definition and whether they have the resources for broad enforcement.
State attorneys general opposed the September delay, according to the Congressional Research Service.
The immediate timeline, however, remains unchanged.
The Clock Is Running Without the Federal Answer Key
The three dates define what happens next.
February 10, 2026: The FDA's 90-day deadline to publish the four documents passed.
November 12, 2026: Cannabinoid products containing compounds not capable of being naturally produced by Cannabis sativa L. will no longer be classified as hemp, to the extent they fall within the Controlled Substances Act's definitions of marijuana or THC.
December 11, 2026: The remaining changes to the federal hemp definition take effect, including the total-THC plant standard, exclusions for synthesized cannabinoids and viable seeds, intermediate-product limits, the direct-to-consumer ban and the 0.4-milligram-per-container cap.
Congress assigned the FDA the responsibility of publishing the scientific lists and clarifying the scope of the term container.
The Congressional Research Service has confirmed that the documents remain unpublished.
The first major restriction does not wait for them.
For hemp manufacturers, the next three days bring a federal classification change. The broader regulatory framework follows on December 11.
The unanswered question is why the agency tasked with providing the definitions has allowed the deadline to pass without publishing them.
Sources
Congressional Research Service. "Delay in Changes to Hemp Definition: Cannabinoids Not Capable of Being Naturally Produced by the Cannabis Plant." Legal Sidebar LSB11496, October 28, 2026. Link
Congressional Research Service. "Hemp Definition Change in the 119th Congress." In Focus IF13136, updated September 28, 2026.
Public Law 119-37, Division B, Section 781 (amending 7 U.S.C. 1639o), via govinfo.
Public Law 119-103, Section 2019 (delay provision).
Marijuana Moment. "FDA Is 9 Months Late In Publishing Legally Mandated Hemp Guidance." November 9, 2026. Link
The Marijuana Herald. Coverage of CRS LSB11496, October 29, 2026. Link
0 comments